AMA urges more physician education on use of once-a-day HIV prevention

| 3 Min Read

The American Medical Association (AMA) adopted new policies today recognizing the need for improved education of physicians on the effective use of pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in high-risk individuals. Tenofovir/emtricitabine (also known as PrEP) is a once-a-day prevention option for HIV-negative men and women that reduces the risk of sexual HIV acquisition. Although the FDA approved PrEP in July 2012, a 2015 survey by the Centers for Disease Control and Prevention (CDC) found that 34 percent of primary care doctors and nurses had never heard of PrEP.

"With more than 1.2 million people in the United States living with substantial risk of HIV infection but fewer than five percent of them taking PrEP, there is significant ground to gain in stemming the incidence of HIV," said AMA Board Member Jesse M. Ehrenfeld, M.D. "Educating physicians about the effective use of PrEP and encouraging insurers to cover the costs associated with its administration will make the transmission of HIV rarer and our nation healthier."

Full press release available when you sign in

Sign in to the AMA website to get the full version of this press release. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Man power walking or jogging, with dumbbells

New changes expand diabetes-prevention for more Medicare patients

| 3 Min Read
Three healthcare workers in discussion

AMA Joy in Medicine points the way to better care

| 5 Min Read
Doctors hold up magnifying glasses over a giant pancreas

Beyond watch and wait: Taking aim at pancreatic cysts

| 7 Min Read
Philip Kuriakose, MD, featured on "Health vs. Hype" AMA podcast

5 things patients should know about microplastics

| 8 Min Read